Case Report
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Cases. Nov 16, 2014; 2(11): 717-723
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.717
Figure 1
Figure 1 Thorax computed tomography-scan before starting chemotherapy (October 2008).
Figure 2
Figure 2 Thorax computed tomography-scan after 8 cycles of treatment. Note stabilization of the disease according to RECIST criteria (June 2009).
Figure 3
Figure 3 Thorax computed tomography-scan after two months of maintenance treatment. Note a partial regression of disease according to RECIST criteria (September 2009).
Figure 4
Figure 4 Thorax computed tomography-scan after 4 mo of maintenance treatment. The disease has completely regressed according to RECIST criteria (November 2009).
Figure 5
Figure 5 Thorax computed tomography-scan showing the complete response after discontinuing bevacizumab (January 2013).
Figure 6
Figure 6 CEA (ng/mL) and CA19. 9 (U/mL) serum levels throughout the treatment and follow-up period.
Figure 7
Figure 7 Thorax computed tomography-scan, showing the response at 60 mo since diagnosis (September 2013).